RA
URGN icon

Rosalind Advisors’s UroGen Pharma URGN Stock Holding History

Rosalind Advisors’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-542,366
Closed -$7.43M – 48
2025
Q2 		$7.43M Sell
542,366
-407,634
-43% -$3.91M 3.52% 14
2025
Q1 		$10.5M Buy
950,000
+80,000
+9% +$853K 5.11% 7
2024
Q4 		$9.27M Buy
+870,000
New +$10.4M 4.74% 8

Other funds holding URGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Rosalind Advisors's URGN Position: Q3 2025 in Review

Rosalind Advisors sold out of UroGen Pharma (URGN) in Q3 2025, closing a stake of 542,366 shares — an estimated $7.43M sold.

Rosalind Advisors first reported a position in URGN in Q4 2024 and held it in 3 quarters. The position peaked at $10.5M in Q1 2025. 161 funds tracked by Wall St. Rank hold URGN as of Q3 2025.

  • Rosalind Advisors reported no remaining UroGen Pharma position as of Q3 2025 after selling out during the quarter.
  • Rosalind Advisors sold 542,366 UroGen Pharma shares in Q3 2025, an estimated $7.43M.
  • Rosalind Advisors first reported a position in UroGen Pharma in Q4 2024 and held it in 3 quarters.
  • Rosalind Advisors's UroGen Pharma position peaked at $10.5M in Q1 2025.
  • 161 funds tracked by Wall St. Rank held UroGen Pharma as of Q3 2025.

Based on Rosalind Advisors's 13F filing for Q3 2025, filed 13 Nov 2025.